Baxalta's corporate venturing unit contributed to the $10m second tranche of the autoimmune disease drug developer's series A round, expected to close at $26m.
US-based autoimmune disease treatment developer Syntimmune raised $10m in series A financing yesterday in a tranche co-led by Baxalta Ventures, the corporate venturing unit of biopharmaceutical company Baxalta.
Venture capital firm Apple Tree Partners co-led the round, which was also backed by Partners Innovation Fund, the corporate venturing arm of healthcare system Partners HealthCare, and undisclosed other investors.
Syntimmune is developing therapeutics based on the neonatal Fc receptor, which is a target for some autoimmune diseases. The cash will go…
